Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

Correspondence to Dr Julio Delgado; jdelgado@clinic.cat ; Dr Manel Juan; mjuan@clinic.cat The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hematopoietic cell transplantation (alloHCT).1 Novel a...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2021-12, Vol.9 (12), p.e003644
Main Authors: Ortiz-Maldonado, Valentín, Rives, Susana, Español-Rego, Marta, Alonso-Saladrigues, Anna, Montoro, Mercedes, Magnano, Laura, Giné, Eva, Pascal, Mariona, Díaz-Beyá, Marina, Castella, Maria, Català, Albert, Faura, Anna, Rodríguez-Lobato, Luis Gerardo, Oliver-Caldes, Aina, Martínez-Roca, Alexandra, Rovira, Montserrat, González-Navarro, E Azucena, Ortega, Juan Ramón, Cid, Joan, Lozano, Miquel, Garcia-Rey, Enric, Fernández, Sara, Castro, Pedro, Jordan, Iolanda, Villamor, Neus, Aymerich, Marta, Torrebadell, Montserrat, Deyà, Àngela, Fernández de Larrea, Carlos, Benitez-Ribas, Daniel, Trias, Esteve, Varea, Sara, Calvo, Gonzalo, Esteve, Jordi, Urbano-Ispizua, Alvaro, Juan, Manel, Delgado, Julio
Format: Article
Language:English
Subjects:
Adolescent
adoptive
Adult
Age
Aged
Antigens, CD19 - immunology
Bone marrow
Cancer
cell engineering
Cell- and Tissue-Based Therapy - methods
Child
Child, Preschool
chimeric antigen
Drug Resistance, Neoplasm
Female
Follow-Up Studies
Humans
Immunotherapy
Letter
Leukemia
Male
Medical prognosis
Middle Aged
Neoplasm Recurrence, Local - immunology
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - therapy
Neurotoxicity
Patients
Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Prognosis
receptors
Receptors, Antigen, T-Cell - immunology
Response rates
Salvage Therapy
Survival Rate
Variables
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Correspondence to Dr Julio Delgado; jdelgado@clinic.cat ; Dr Manel Juan; mjuan@clinic.cat The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hematopoietic cell transplantation (alloHCT).1 Novel agents such as inotuzumab ozogamicin or blinatumomab achieve increased response rates, but these are generally transient unless followed by alloHCT. Patients with ≥5% lymphoblasts in the BM had a higher incidence of CRS (any grade: 82% vs 39%, p=0.0022; grade ≥3: 27% vs 0%, p=0.0036) compared with those with
ISSN:2051-1426
2051-1426
DOI:10.1136/jitc-2021-003644